U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry ACHIRAL
Molecular Formula C20H21NO2.ClH
Molecular Weight 343.847
Optical Activity NONE
Defined Stereocenters 0 / 0
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of MOXAVERINE HYDROCHLORIDE

SMILES

Cl.CCC1=NC(CC2=CC=CC=C2)=C3C=C(OC)C(OC)=CC3=C1

InChI

InChIKey=DULZSDGCXSLVAQ-UHFFFAOYSA-N
InChI=1S/C20H21NO2.ClH/c1-4-16-11-15-12-19(22-2)20(23-3)13-17(15)18(21-16)10-14-8-6-5-7-9-14;/h5-9,11-13H,4,10H2,1-3H3;1H

HIDE SMILES / InChI

Molecular Formula ClH
Molecular Weight 36.461
Charge 0
Count
Stereochemistry ACHIRAL
Additional Stereochemistry No
Defined Stereocenters 0 / 0
E/Z Centers 0
Optical Activity NONE

Molecular Formula C20H21NO2
Molecular Weight 307.3862
Charge 0
Count
Stereochemistry ACHIRAL
Additional Stereochemistry No
Defined Stereocenters 0 / 0
E/Z Centers 0
Optical Activity NONE

Moxaverine, a derivative of papaverine, is a phosphodiesterase inhibitor. Moxaverine has been studied in phase III of a clinical trial for the treatment of ocular blood flow in patients with age- related macular degeneration and primary open angle glaucoma. In addition, it has been studied in phase II of the clinical trial for the treatment of ischemia. This compound is prohibited by FEI (International Federation of equine).

Approval Year

Targets

Targets

Primary TargetPharmacologyConditionPotency
Conditions

Conditions

ConditionModalityTargetsHighest PhaseProduct
Primary
Unknown

Approved Use

Unknown
Primary
Unknown

Approved Use

Unknown
Primary
Unknown

Approved Use

Unknown
PubMed

PubMed

TitleDatePubMed
Construction and validation of a microprocessor controlled extracorporal circuit in rats for the optimization of isolated limb perfusion.
2004 Dec
Tissue distribution of moxaverine-hydrochloride in the rabbit eye and plasma.
2005 Jun
Effect of systemic moxaverine on ocular blood flow in humans.
2009 Nov
Patents

Patents

Sample Use Guides

intravenous infusion of 150 mg in 250 ml NaCl, applied over 30 minutes.
Route of Administration: Intravenous
In Vitro Use Guide
Using a combination of techniques to assess quantitatively the shape and the filterability of red blood cells (RBC) after exposure to stress conditions (400 mosmol/l, lactacidosis, pH 6.8), the effects of 1-benzyl-3-ethyl-6,7-dimethoxy-isoquinoline hydrochloride (moxaverine-HCl, Kollateral) were tested. The shape of freely suspended RBC was quantified using the tangent count procedure. Moxaverine, when present in doses between 10(-5) und 10(-2) mol/l while the RBC are stressed, restored both the normal discoid red cell configuration and the microrheological performance when tested under low shear stresses. The data showed that moxaverine exerted protective effects on RBC membrane curvature and whole cell microrheological behavior (performance).
Substance Class Chemical
Created
by admin
on Thu Jul 06 01:49:52 UTC 2023
Edited
by admin
on Thu Jul 06 01:49:52 UTC 2023
Record UNII
6R0I0E99CN
Record Status Validated (UNII)
Record Version
  • Download
Name Type Language
MOXAVERINE HYDROCHLORIDE
MI   WHO-DD  
Common Name English
1-BENZYL-6,7-DIMETHOXY-3-ETHYLISOQUINOLINE HYDROCHLORIDE
Systematic Name English
MOXAVERINE HYDROCHLORIDE [MI]
Common Name English
EUPAVERIN
Brand Name English
Moxaverine hydrochloride [WHO-DD]
Common Name English
PAVERINE HYDROCHLORIDE
Common Name English
KOLLATERAL
Brand Name English
EUPAVERINA
Brand Name English
MOXAVERINE HCL
Common Name English
Code System Code Type Description
ECHA (EC/EINECS)
214-607-5
Created by admin on Thu Jul 06 01:49:52 UTC 2023 , Edited by admin on Thu Jul 06 01:49:52 UTC 2023
PRIMARY
DRUG BANK
DBSALT002165
Created by admin on Thu Jul 06 01:49:52 UTC 2023 , Edited by admin on Thu Jul 06 01:49:52 UTC 2023
PRIMARY
RXCUI
236673
Created by admin on Thu Jul 06 01:49:52 UTC 2023 , Edited by admin on Thu Jul 06 01:49:52 UTC 2023
PRIMARY RxNorm
EPA CompTox
DTXSID80151342
Created by admin on Thu Jul 06 01:49:52 UTC 2023 , Edited by admin on Thu Jul 06 01:49:52 UTC 2023
PRIMARY
CAS
1163-37-7
Created by admin on Thu Jul 06 01:49:52 UTC 2023 , Edited by admin on Thu Jul 06 01:49:52 UTC 2023
PRIMARY
FDA UNII
6R0I0E99CN
Created by admin on Thu Jul 06 01:49:52 UTC 2023 , Edited by admin on Thu Jul 06 01:49:52 UTC 2023
PRIMARY
MERCK INDEX
M7644
Created by admin on Thu Jul 06 01:49:52 UTC 2023 , Edited by admin on Thu Jul 06 01:49:52 UTC 2023
PRIMARY Merck Index
SMS_ID
100000085685
Created by admin on Thu Jul 06 01:49:52 UTC 2023 , Edited by admin on Thu Jul 06 01:49:52 UTC 2023
PRIMARY
PUBCHEM
70881
Created by admin on Thu Jul 06 01:49:52 UTC 2023 , Edited by admin on Thu Jul 06 01:49:52 UTC 2023
PRIMARY
EVMPD
SUB03341MIG
Created by admin on Thu Jul 06 01:49:52 UTC 2023 , Edited by admin on Thu Jul 06 01:49:52 UTC 2023
PRIMARY
Related Record Type Details
PARENT -> SALT/SOLVATE